Form 4: Arrowhead Pharmaceuticals Director Sells Shares Under 10b5-1 Trading Plan

Victoria Vakiener, a director of Arrowhead Pharmaceuticals, sold 1,799 shares of common stock at an average price of $23.31 on May 2, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On May 2, 2024, Victoria Vakiener, a director of Arrowhead Pharmaceuticals, sold 1,799 shares of the company's common stock.
• The sale was executed under a 10b5-1 trading plan.
• The shares were sold at a weighted average price of $23.31, with individual transaction prices ranging from $23.05 to $23.46.
• Following the transaction, Vakiener beneficially owns 30,205 shares, including shares underlying restricted stock units subject to vesting conditions.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine sale under a pre-arranged trading plan and doesn't necessarily indicate a negative outlook on the company.

Industry Context

Sales by company insiders are a common occurrence and are often pre-planned through 10b5-1 trading plans to avoid accusations of trading on non-public information. The market typically views these sales in the context of the individual's overall holdings and the reasons behind the sale.

Comparison to Industry Standards

• Insider sales are a regular part of corporate governance, with companies like Alnylam Pharmaceuticals and Ionis Pharmaceuticals also seeing insider transactions.
• The use of 10b5-1 plans is a standard practice among executives and directors to manage their stock holdings while complying with insider trading regulations.
• The size of the transaction is relatively small compared to the overall market capitalization of Arrowhead Pharmaceuticals.

Stakeholder Impact

• The sale may have a minor impact on shareholder sentiment, but is unlikely to significantly affect the company's operations or financial performance.

Key Dates